Gap19, a peptide derived from nine amino acids of the Cx43 cytoplasmic loop (CL), is a potent and selective connexin 43 (Cx43) hemichannel blocker. Gap19 inhibits hemichannels caused by preventing intramolecular interactions of the C-terminus (CT) with the CL. Gap19 is not blocking GJ channels or Cx40/pannexin-1 hemichannels. Gap19 has protective effects against myocardial^[1][2].

Cx43 Hemichannel^[1]

Gap19 (250 μM; for 30 min ) decreases mitochondrial potassium uptake^[1].
Gap19 (400 μM) inhibits unitary hemichannel currents in HeLa-Cx43 cells^[2].
Gap19 (100 μM) inhibits hemichannel unitary currents in ventricular cardiomyocytes^[2].
Gap19 (250 μM, 30 min) protects against myocardial ischemia/reperfusion injury in vitro and in vivo^[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Gap19 (iv; 25 mg/kg; 10 min before ligation) significantly reduces the infarct size by approximately one-fifth^[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

1161.44

C₅₅H₉₆N₁₄O₁₃

1507930-57-5

KQIEIKKFK

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Boengler K, et al. Connexin 43 impacts on mitochondrial potassium uptake. Front Pharmacol. 2013 Jun 6;4:73.

  [2]. Wang N, et al. Selective inhibition of Cx43 hemichannels by Gap19 and its impact on myocardial ischemia/reperfusion injury. Basic Res Cardiol. 2013 Jan;108(1):309.